Search Results - "Karandeeva, T. V."

Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study by Kovalenko, E. I., Artamonova, E. V., Bolotina, L. V., Zhiliaeva, L. A., Ponomarenko, D. M., Karabina, E. V., Mukhametshina, G. Z., Khasanova, A. I., Ratner, E. Yu, Safarova, A. R., Manikhas, A. G., Popova, N. O., Evstigneeva, I. V., Vladimirova, L. Yu, Kramskaya, L. V., Karandeeva, T. V., Suslova, I. R., Romanchuk, O. V., Shikina, V. E., Povyshev, A. Yu, Osipov, M. A., Cherniakova, E. M., Dergunov, A. S., Volkonskiy, M. V., Chernov, I. S., Shumskaya, I. E., Fael, M. M., Garifullina, V. I., Gudkova, I. E.

“…Introduction . The standard of 1st line treatment of HER2+ metastatic breast cancer (mBC) is double blockade with trastuzumab and pertuzumab + taxane, 2nd…”
Get full text

THE USE OF HYDRAZINE SULFATE IN OPTIMIZATION OF PALLIATIVE MEDICAL THERAPY AND IMPROVEMENT OF QUALITY OF LIFE IN CANCER PATIENTS by S. V. Strazhev, A. Yu. Berezantsev, T. V. Karandeeva, A. A. Drobyazko

“…The article discusses the quality of life and the necessity of optimization of medical therapy in patients with cancer receiving palliative care. The…”
Get full text